Product logins

Find logins to all Clarivate products below.


: Drugs to Watch 2018

Here you will find relevant articles and insight into all Clarivate related products and news.

Blog October 31, 2018
Indivior’s Sublocade contributing to transformation of opioid dependence market
Blockbuster drugs buprenorphine Cortellis
Blog October 3, 2018
Erleada gains first-mover advantage in CRPC
apalutamide Blockbuster drugs Cortellis
Blog August 29, 2018
First-ever RNAi drug Onpattro (patisiran) approved in U.S. for hereditary transthyretin-mediated amyloidosis
Alnylam Blockbuster drugs Cortellis
Blog August 15, 2018
Biktarvy poised to help Gilead recapture share in the HIV market
Biktarvy Blockbuster drugs Cortellis
Blog August 1, 2018
GW’s Epidiolex becomes the first cannabinoid-based drug approved for epilepsy
Blockbuster drugs cannabinoid childhood epilepsy
Blog May 23, 2018
FDA approval of first-in-class Aimovig set to transform the migraine market
Aimovig Cortellis Cortellis Competitive Intelligence
Blog March 22, 2018
Record number of blockbusters forecast for 2018 launch as the pace of pharmaceutical innovation accelerates
Amgen Blockbuster drugs cannabidiol-based medicine

Drugs to Watch 2018

Blog October 31, 2018
Indivior’s Sublocade contributing to transformation of opioid dependence market
Blog October 3, 2018
Erleada gains first-mover advantage in CRPC
Blog August 29, 2018
First-ever RNAi drug Onpattro (patisiran) approved in U.S. for hereditary transthyretin-mediated amyloidosis
Blog August 15, 2018
Biktarvy poised to help Gilead recapture share in the HIV market
Blog August 1, 2018
GW’s Epidiolex becomes the first cannabinoid-based drug approved for epilepsy
Blog May 23, 2018
FDA approval of first-in-class Aimovig set to transform the migraine market
Blog March 22, 2018
Record number of blockbusters forecast for 2018 launch as the pace of pharmaceutical innovation accelerates